- Home
- VLGEA vs MNPR Comparison
VLGEA vs MNPR Comparison
Compare VLGEA & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VLGEA | MNPR |
|---|---|---|
| Founded | 1937 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.4M | 421.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | VLGEA | MNPR |
|---|---|---|
| Price | $38.29 | $66.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $101.42 |
| AVG Volume (30 Days) | 45.4K | ★ 308.4K |
| Earning Date | 03-03-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.69% | N/A |
| EPS Growth | ★ 7.88 | N/A |
| EPS | ★ 3.75 | N/A |
| Revenue | ★ $2,345,586,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.90 | ★ N/A |
| Revenue Growth | ★ 3.88 | N/A |
| 52 Week Low | $30.08 | $26.06 |
| 52 Week High | $40.15 | $105.00 |
Technical Indicators
Market Signals| Indicator | VLGEA | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 71.13 | 46.83 |
| Support Level | $33.80 | $60.00 |
| Resistance Level | $35.78 | $76.13 |
| Average True Range (ATR) | 1.08 | 4.93 |
| MACD | 0.34 | -0.15 |
| Stochastic Oscillator | 100.00 | 42.78 |
Price Performance
Historical ComparisonAbout VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.